Recce Pharmaceuticals

We invite shareholders and interested parties to engage with the Recce leadership team via our interactive investor hub.

Innovative Anti-Infective Technology with Global Recognition

Significant Clinical and Preclinical Progress

Strong Financial Backing and Government Support

Strategic Global Partnerships

Why Invest

Corporate Governance

News and Media

Announcements

Home

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Asia presents vast opportunities for clinical trials and commercialisation. With a population nearing 700 million and a combined GDP double that of Australia, Southeast Asia’s healthcare demand is rising due to an aging population and increasing prevalence of chronic diseases like diabetes. 

Recce Pharmaceuticals has already making inroads, leveraging partnerships to address pressing health challenges like antimicrobial resistance and infections. 

RECCE® 327 topical gel (R327G) has been shown to be safe and well tolerated across human subjects, with indications of promising antibacterial responses observed in patients. The successful dosing of 15 patients in its Phase 2 Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) clinical trial represents a significant opportunity to expand the application of R327G formulation. 

ABSSSIs are a significant healthcare concern, with clinical trials addressing indications such as DFIs, necrotizing fasciitis, and post-operative wound infections. The global ABSSSI market size was estimated to be USD $1.34 billion in 2023 and is expected to reach USD $2.31 billion in the next 10 years.